

## COVID-19 Breakthrough Infections Clark County, Nevada

**Date: May 13, 2021**

Breakthrough cases are U.S. residents with a SARS-CoV2 RNA or antigen detected on respiratory specimen collected greater than or equal to 14 days after completing the primary series of an FDA authorized COVID-19 vaccine (i.e., complete vaccination). Complete vaccination is two doses of the Pfizer or Moderna vaccine or one dose of the Johnson and Johnson (Janssen) vaccine.

Given the large number of people being vaccinated in the United States and the high level of ongoing SARS-CoV-2 circulation, thousands of symptomatic vaccine breakthrough cases are expected, even if the vaccines remain as effective as demonstrated during the clinical trials.

The Centers for Disease Control and Prevention (CDC) recently updated guidance on reporting of breakthrough infections to only report those that have been hospitalized and contacted by public health and an interview is performed or are a recorded COVID-19 death. As with other metrics related to COVID-19 disease investigation and contact tracing, this information is self-reported by the individual. Due the small number of associated deaths, further breakdowns are not provided at this time to protect privacy and confidentiality. Data is considered preliminary and subject to change.

As of today, Southern Nevada Health District is reporting a total of 26 breakthrough hospitalizations and 2 breakthrough deaths in Clark county, Nevada.

**Table 1: Population Characteristics of COVID-19 Breakthrough Hospitalizations**

	<i>Overall</i>
	<i>N %</i>
<i>All</i>	<u>26 100</u>
<b>Age (in years)</b>	
25-49	2 8
50-64	3 12
65+	21 81
<b>Gender</b>	
Male	18 69
Female	8 31
<b>Race/Ethnicity</b>	
Hispanic	5 19
White	15 58
Black	3 12
API	2 8
Other	1 4
<b>Travel History</b>	
Yes	1 4
No	20 77
Unknown	5 19
<b>Variant of concern (VOC)</b>	
P.1	1 4
Unknown	25 96
<b>Death</b>	
Yes	2 8
No	18 69
Unknown	6 23
<b>Vaccine Type</b>	
Pfizer	7 27
Moderna	4 15
Janssen	5 19
Unknown	10 38
<b>Underlying Conditions</b>	
Yes	21 81
No	5 19

**Table 2: Breakdown of COVID-19 Breakthrough Hospitalizations according to Underlying conditions**

	<i>Overall</i>
	<i>N %</i>
<i>All</i>	21 100
<b><i>Diabetes</i></b>	
<i>Yes</i>	5 24
<i>No</i>	16 76
<b><i>Hypertension</i></b>	
<i>Yes</i>	14 67
<i>No</i>	7 33
<b><i>Chronic Lung Disease</i></b>	
<i>Yes</i>	5 24
<i>No</i>	16 76
<b><i>Chronic Heart Disease</i></b>	
<i>Yes</i>	6 29
<i>No</i>	15 71
<b><i>Chronic Liver Disease</i></b>	
<i>No</i>	21 100
<b><i>Chronic Kidney Disease</i></b>	
<i>Yes</i>	2 10
<i>No</i>	19 90
<b><i>Neurological Conditions</i></b>	
<i>No</i>	21 100
<b><i>Immunocompromised</i></b>	
<i>Yes</i>	3 14
<i>No</i>	18 86
<b><i>Other conditions</i></b>	
<i>Yes</i>	11 52
<i>No</i>	10 48
<b><i>Unknown</i></b>	
<i>No</i>	21 100

**Notes:**

\* White, Black, Asian, and AEA are non-Hispanic

\* AEA=American Indian/Eskimos/Alaskan Natives API=Asian Pacific Islander

\* There are a limited number of specimens for sequencing of VOCs compared to the total number of all COVID-19 cases; 'Unknown' does not necessarily mean cases were not VOC

\* The report does not include breakthrough hospitalizations from State approved facilities as State is responsible for their investigation.

\* Given the low number of breakthrough deaths, detailed information is not provided to protect confidentiality of the cases .